Drug Profile
Revusiran
Alternative Names: ALN-TTRsc; SAR438714; siTTRscLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Class Heart failure therapies; Small interfering RNA
- Mechanism of Action Prealbumin inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Familial amyloid neuropathy; Transthyretin-related hereditary amyloidosis
Most Recent Events
- 08 Feb 2017 Alnylam Pharmaceuticals terminates a phase III extension trial for Transthyretin-related hereditary amyloidosis (In the elderly, In adults) due to safety findings in United Kingdom (SC) (EudraCT2015-005333-49)
- 01 Feb 2017 Alnylam Pharmaceuticals completes a phase II trial in Familial amyloid neuropathy in France, Germany, Portugal, Sweden, United Kingdom (SC) (NCT02595983)
- 01 Nov 2016 Alnylamt terminates a phase III trial in Transthyretin-related hereditary amyloidosis (In adults, In the elderly) due to unacceptable risk benefit profile in USA, United Kingdom, Belgium, Canada, France, Germany, Italy, Sweden and Spain (SC) (NCT02319005)